XORTX Therapeutics Past Earnings Performance

Past criteria checks 0/6

XORTX Therapeutics's earnings have been declining at an average annual rate of -22.6%, while the Pharmaceuticals industry saw earnings growing at 43.4% annually.

Key information

-22.6%

Earnings growth rate

-5.6%

EPS growth rate

Pharmaceuticals Industry Growth23.1%
Revenue growth raten/a
Return on equity-34.5%
Net Marginn/a
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

Here's Why We're Watching XORTX Therapeutics' (CVE:XRTX) Cash Burn Situation

Aug 23
Here's Why We're Watching XORTX Therapeutics' (CVE:XRTX) Cash Burn Situation

XORTX Therapeutics (CVE:XRTX) Is In A Strong Position To Grow Its Business

Apr 01
XORTX Therapeutics (CVE:XRTX) Is In A Strong Position To Grow Its Business

We're Interested To See How XORTX Therapeutics (CVE:XRTX) Uses Its Cash Hoard To Grow

Dec 16
We're Interested To See How XORTX Therapeutics (CVE:XRTX) Uses Its Cash Hoard To Grow

Companies Like XORTX Therapeutics (CSE:XRX) Can Afford To Invest In Growth

Sep 01
Companies Like XORTX Therapeutics (CSE:XRX) Can Afford To Invest In Growth

Revenue & Expenses Breakdown

How XORTX Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TSXV:XRTX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-120
30 Jun 240-121
31 Mar 240-321
31 Dec 230-222
30 Sep 230-724
30 Jun 230-725
31 Mar 230-726
31 Dec 220-827
30 Sep 220135
30 Jun 220-324
31 Mar 220-223
01 Jan 220-221
30 Sep 210-910
30 Jun 210-310
31 Mar 210-310
31 Dec 200-110
30 Sep 200-110
30 Jun 200-100
31 Mar 200000
31 Dec 190000
30 Sep 190000
30 Jun 190-100
31 Mar 190-100
31 Dec 180-310
30 Sep 180-310
30 Jun 180-310
31 Mar 180-310
31 Dec 170000
30 Sep 170000
30 Jun 170000
31 Mar 170000
31 Dec 160000

Quality Earnings: XRTX is currently unprofitable.

Growing Profit Margin: XRTX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: XRTX is unprofitable, and losses have increased over the past 5 years at a rate of 22.6% per year.

Accelerating Growth: Unable to compare XRTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: XRTX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-44%).


Return on Equity

High ROE: XRTX has a negative Return on Equity (-34.53%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies